LLY Jul 2024 740.000 call
| Previous Close | 42.75 |
| Open | 43.40 |
| Bid | 48.15 |
| Ask | 49.10 |
| Strike | 740.00 |
| Expire Date | 2024-07-19 |
| Day's Range | 42.75 - 43.40 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 239 |
- Reuters
Wegovy weight loss sustained for four years in trial, Novo Nordisk says
Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday. Novo presented the new long-term data at the European Congress on Obesity in Venice, Italy, gleaned from a large study for which much of the results had been published last year. "This is the longest study we've conducted so far of semaglutide for weight loss," Martin Holst Lange, Novo's head of development, said in an interview, referring to the active ingredient in Wegovy and the company's diabetes drug Ozempic.
ZacksPharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA panel meeting to discuss Eli Lilly's (LLY) donanemab is set to take place on Jun 10.
Investor's Business DailyHow A Top Fund Beats The Market By Owning Future Leaders
Julianne McHugh, lead manager of best mutual fund BNY Mellon Large Cap Securities, isn't interested in blue-chip stars of yesteryear.
